Cowen & Co Upgrades Incyte (INCY) to Outperform
INCY Hot Sheet
Rating Summary:9 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 24 | Down: 13 | New: 29
Cowen & Co upgrades Incyte (Nasdaq: INCY) from Neutral to Outperform.
To see more analyst ratings on INCY Click Here.
Incyte Corporation, a drug discovery and development company, focuses on developing proprietary small molecule drugs to treat oncology, inflammation, and diabetes.
To see more analyst ratings on INCY Click Here.
Incyte Corporation, a drug discovery and development company, focuses on developing proprietary small molecule drugs to treat oncology, inflammation, and diabetes.
You May Also Be Interested In
- UPDATE: Nomura Securities Upgrades ASML Inc. (ASML) to Buy; Revenue Outlook Underestimated
- UPDATE: UBS Downgrades Cavium Networks (CAVM) to Neutral; Changing Stance; Cutting Estimates
- BofA/Merrill Lynch Upgrades Synacor (SYNC) to Neutral
Create E-mail Alert Related Categories
UpgradesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
